Orchid Pharma Share News - Latest Updates, Live News & More

Latest news about Orchid Pharma

Orchid Pharma Acquires Global Rights to Enmetazobactam, Reports Q1 Revenue Decline 3 days ago

Orchid Pharma has acquired global rights to Enmetazobactam and the trademark Exblifep from Allecra, pending completion within three months. The company reported Q1 sales of ₹173.00 crores, a 29% decrease from the previous year, with gross margins at 42% and operational EBITDA at ₹14.00 crores. The decline is attributed to a global slowdown in the antibiotics market, with both prices and volumes under pressure. Despite challenges, Orchid is progressing on strategic initiatives including domestic brand Orblicef, expanding its Antimicrobial Stewardship division, and advancing projects like 7ACA and Cefiderocol.

Orchid Pharma Reports Mixed Q1 Results, Implements Cost-Cutting Measures 5 days ago

Orchid Pharma Reports Q1 Results: Profit Dips Amid Revenue Decline 5 days ago

Orchid Pharma Secures French Court Approval for Allecra Therapeutics Asset Acquisition Aug 05, 2025

Orchid Pharma Shares Surge as Company Reclaims Global Rights to Novel Antibiotic Jul 31, 2025

More news about Orchid Pharma

30Jul 25

Orchid Pharma Secures Global Rights to Enmetazobactam Through Strategic Asset Acquisitions

Orchid Pharma has acquired assets from Allecra Therapeutics in Germany and France, securing 100% global ownership of Enmetazobactam, a novel antibiotic. The company also established Orchid Pharma Europe GmbH as a wholly-owned subsidiary in Germany. These strategic moves consolidate Orchid Pharma's control over the antibiotic, known as EXBLIFEP internationally and Orblicef in India, marking the full repatriation of the first novel antibiotic discovered in India back to its home country.

30Jul 25

Orchid Pharma Expands European Presence with German Subsidiary Acquisition

Orchid Pharma Limited has made two strategic moves to strengthen its position in the European market. The company acquired a German subsidiary, now renamed Orchid Pharma Europe GmbH, for €28,500. Additionally, Orchid Pharma is in the process of acquiring all assets related to Enmetazobactam, a novel antibiotic molecule, from Allecra Therapeutics in Germany and France. These acquisitions aim to enhance Orchid Pharma's global footprint, expand its product portfolio, and consolidate ownership of a key antibiotic developed in India.

17Jul 25

Orchid Pharma Secures ₹1,425 Crore Funding from HDFC Bank for Cefiderocol Project

Orchid Pharma Limited has entered into an agreement with HDFC Bank Limited for credit facilities totaling ₹1,425.00 crore. The funding is specifically allocated for setting up the Cefiderocol project, which involves a novel siderophore cephalosporin antibiotic. The company executed a Deed of Hypothecation with HDFC Bank to secure the credit facilities. This development has been reported to stock exchanges in compliance with SEBI regulations.

06Jun 25

NCLT Ruling on Orchid Pharma-DBS Bank Dispute: Potential Financial Implications Loom

The National Company Law Tribunal (NCLT) has issued a ruling in the legal dispute between Orchid Pharma Limited and DBS Bank. While specific details are undisclosed, the ruling is expected to significantly impact Orchid Pharma's financial landscape. Orchid Pharma's recent financial metrics show improvements, with total assets up 26.89%, total equity increased by 66.43%, and current assets growing by 58.42% year-over-year. Both current and non-current liabilities have decreased. The company's strengthened financial position may help mitigate potential adverse effects from the ruling.

29May 25

Orchid Pharma Receives USFDA's EIR with VAI Status

Orchid Pharma has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA). This follows the USFDA's acceptance of Orchid Pharma's response to previous inspection observations. The VAI status indicates that while minor issues were found, they don't require significant regulatory action. This outcome is viewed positively in the pharmaceutical industry, suggesting that Orchid Pharma has adequately addressed the USFDA's concerns and can continue operations without major regulatory hurdles in the U.S. market.

27May 25

Orchid Pharma Reports Q4 Revenue Growth Amid EBITDA Margin Pressure

Orchid Pharma's Q4 results show a 9.40% YoY revenue increase to Rs 2,375.00 million, with 9.30% QoQ growth. EBITDA declined 3.20% YoY but rose 6.10% QoQ to Rs 280.00 million. EBITDA margin decreased to 11.80%, down 154 bps YoY and 35 bps QoQ, indicating profitability challenges despite revenue growth.

26May 25

Orchid Pharma Reports Q4 Revenue Growth and Improved EBITDA, Despite Profit Dip

Orchid Pharma's Q4 results show revenue growth of 9.22% YoY to ₹2,370.00 million and improved EBITDA of ₹343.30 million. However, net profit declined 16.11% YoY to ₹278.50 million. The company saw a sequential profit improvement of 16.53% from Q3.

09Apr 25

Orchid Pharma Settles Dispute with DBS India Bank for ₹7.62 Crore

Orchid Pharma has resolved a long-standing dispute with DBS Bank India Limited through a Joint Memorandum of Compromise. The settlement, worth ₹7.62 crore, covers lease rentals for a property in Tamil Nadu from April 2020 to December 2024. The agreement includes closing pending NCLT cases, preventing future legal actions by DBS Bank, and establishing a new lease agreement for the property. This resolution allows Orchid Pharma to eliminate uncertainty, potentially reduce legal expenses, and secure continued access to the property.

20Feb 25

Orchid Pharma's Alathur API Facility Aces USFDA Inspection, Retains Exclusive Status

Orchid Pharma's API facility in Alathur, Tamil Nadu, successfully passed a surprise USFDA inspection with minor observations, maintaining its status as India's only USFDA-approved facility for Sterile Cephalosporins. The facility also renewed its EU GMP certificate, reinforcing its global market position in antibiotic manufacturing. These achievements validate the company's compliance with international regulatory standards and strengthen its ability to supply high-quality APIs to global markets.